| Ident. | Authors (with country if any) | Title |
|---|
| 000053 (2016) |
Haiying Sun [États-Unis] ; Linh M. Van [États-Unis] ; David Floch [Suisse] ; Xuemin Jiang [États-Unis] ; Ulf R. Klein [Suisse] ; Ken Abrams [États-Unis] ; Gangadhar Sunkara [États-Unis] | Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis |
| 000081 (2016) |
Elisabeth Lobner [Autriche] ; Michael W. Traxlmayr [Autriche, États-Unis] ; Christian Obinger [Autriche] ; Christoph Hasenhindl [Autriche] | Engineered IgG1‐Fc – one fragment to bind them all |
| 000180 (2015) |
Andreas Kronbichler [Autriche, Royaume-Uni] ; David R. W. Jayne [Royaume-Uni] ; Gert Mayer [Autriche] | Frequency, risk factors and prophylaxis of infection in ANCA‐associated vasculitis |
| 000247 (2014) |
Caroline Whately-Smith [Royaume-Uni] ; Claire Watkins [Royaume-Uni] ; Helen Mann [Royaume-Uni] ; Chrissie Fletcher [Royaume-Uni] ; Pierre Ducournau [Suisse] | Utility values in health technology assessments: a statistician's perspective |
| 000306 (2014) |
J. Kluk [Royaume-Uni] ; M. Rustin [Royaume-Uni] ; P. A. Brogan [Royaume-Uni] ; E. Omoyinmi [Royaume-Uni] ; D. M. Rowczenio [Royaume-Uni] ; L. C. Willcocks [Royaume-Uni] ; L. Melly [Royaume-Uni] ; H. J. Lachmann [Royaume-Uni] | Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome: a report of a novel mutation and review of the literature |
| 000508 (2013) |
I. M. Catlett [États-Unis] ; X. Luo [États-Unis] ; M. S. Penney [États-Unis] ; M. E. Pray [États-Unis] ; G. Spencer-Green [États-Unis] ; M. Botfield [États-Unis] ; T. Hoock [États-Unis] | THU0141 Biomarker assessment of VX-509, an investigational selective JAK3 inhibitor, in healthy volunteers |
| 000561 (2013) |
A. P. Malaviya [Royaume-Uni] | SP0134 Refractory rheumatoid arthritis; all the therapeutic arrows spent? |
| 000904 (2013) |
G. Burmester [Allemagne] ; T. Takeuchi [Japon] ; O. Barbarash [Russie] ; G. Ranganna [Royaume-Uni] ; D. Close [Royaume-Uni] ; A. Godwood [Royaume-Uni] ; D. Saurigny [Royaume-Uni] | FRI0232 Consistent efficacy and safety outcomes between european and japanese subjects with rheumatoid arthritis following treatment with mavrilimumab in the phase 2 earth study |
| 000952 (2013) |
C.-Y. Wu [États-Unis] ; X. Chen [États-Unis] ; H. Lu [États-Unis] ; E. Esfandiari ; F. Magrini ; A. Godwood [Royaume-Uni] ; P. Ryan ; C. Kane [États-Unis] ; L. Roskos [États-Unis] ; B. Wang [États-Unis] | FRI0182 Pharmacokinetics and immunogenicity of mavrilimumab administered subcutaneously in subjects with rheumatoid arthritis |
| 000955 (2013) |
A. Östör [Royaume-Uni] ; J. A. Román Ivorra [Espagne] ; J. Wollenhaupt [Allemagne] ; C. Mpofu [Suisse] ; C. Bernasconi [Suisse] ; J. Sibilia [France] ; V. Bykerk [États-Unis, Canada] | FRI0179 Comparison of tocilizumab as monotherapy or in combination with non-biological disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) and an inadequate response to anti-TNF agents |
| 000A20 (2013) |
B. Strober [États-Unis, Canada] ; M. Buonanno [États-Unis] ; J. D. Clark [États-Unis] ; T. Kawabata [États-Unis] ; H. Tan [États-Unis] ; R. Wolk [États-Unis] ; H. Valdez [États-Unis] ; R. G. Langley [Canada] ; J. Harness [Suisse] ; A. Menter [États-Unis] ; K. Papp [Canada] | Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment |
| 000B73 (2013) |
S. Spitz [États-Unis] ; D. Wilkins [États-Unis] ; E. Esfandiari [Royaume-Uni] ; A. Godwood [Royaume-Uni] ; L. Roskos [États-Unis] ; P. Ryan [États-Unis] ; F. Magrini [Royaume-Uni] | AB0576 Evaluation of surfactant protein-D and KL-6 as potential pulmonary safety biomarkers during mavrilimumab treatment |
| 000B77 (2013) |
S. Menon [États-Unis] ; K. Barker [États-Unis] ; E. Peeva [États-Unis] ; I. Gourley [États-Unis] ; A. Heatherington [États-Unis] | AB0572 Meta-analysis of the key rheumatoid arthritis (RA) disease activity endpoints in patients treated with B-cell depleting therapies |
| 000E68 (2012) |
Vivian P. Bykerk [États-Unis, Canada] ; Andrew J K. Östör [Royaume-Uni] ; José Alvaro-Gracia [Espagne] ; Karel Pavelka [République tchèque] ; José Andrés Román Ivorra [Espagne] ; Winfried Graninger [Autriche] ; William Bensen [Canada] ; Michael T. Nurmohamed [Pays-Bas] ; Andreas Krause [Allemagne] ; Corrado Bernasconi [Suisse] ; Andrea Stancati [Suisse] ; Jean Sibilia [France] | Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice |
| 000F49 (2012) |
Anshuman P. Malaviya [Royaume-Uni, Niger] ; Andrew J. K. Östör [Royaume-Uni] | Rheumatoid arthritis and the era of biologic therapy |
| 000F94 (2012) |
Sooha Kim [Royaume-Uni] ; Andrew J. K. Östör [Royaume-Uni] ; Muhammad K. Nisar [Royaume-Uni] | Interleukin-6 and cytochrome-P450, reason for concern? |
| 001134 (2011) |
Gerd R. Burmester [Allemagne] ; Eugen Feist [Allemagne] ; Matthew A. Sleeman [Royaume-Uni] ; Bing Wang [États-Unis] ; Barbara White [États-Unis] ; Fabio Magrini [Royaume-Uni] | Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study |
| 001145 (2011) |
S. Van Assen [Pays-Bas] ; N. Agmon-Levin [Israël] ; O. Elkayam [Israël] ; R. Cervera [Espagne] ; M F Doran [Irlande (pays)] ; M. Dougados [France] ; P. Emery [Royaume-Uni] ; P. Geborek [Suède] ; J P A. Ioannidis [États-Unis, Grèce] ; D R W. Jayne [Royaume-Uni] ; C G M. Kallenberg [Pays-Bas] ; U. Müller-Ladner [Allemagne] ; Y. Shoenfeld [Israël] ; L. Stojanovich [Serbie] ; G. Valesini [Italie] ; N M Wulffraat [Pays-Bas] ; M. Bijl [Grèce] | EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases |
| 001206 (2011) |
Taras Gout [Royaume-Uni] ; Andrew J. K. Östör [Royaume-Uni] ; Muhammad K. Nisar [Royaume-Uni] | Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review |
| 001489 (2009) |
David Jayne [Royaume-Uni] | Treatment of ANCA‐associated systemic small‐vessel vasculitis |
| 001626 (2007) |
Annabel Kuek [Royaume-Uni] ; Brian L. Hazleman [Royaume-Uni] ; Andrew J K. Östör [Royaume-Uni] | Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution |
